In the USA the estimated C2 deficiency is the most common complement deficiency with frequency estimates between 0.5 to 1 in 10,000 for homozygous C2-deficient patients. Complement deficiencies cause susceptibility not only to bacterial infection but also to autoimmune disease. Patients with specific complement deficiencies are especially prone to SLE; lupus develops in approximately 90% of C1q-null, 75% of C4-null, and up to 30% of C2-null individuals.
Comprehensive insight on patient segmentation based on age, sex, types (classical, lectin & alternative), Signs & Symptoms, segmentation by disease condition (Recurrent bacterial infections, Systemic lupus erythematosus, Angioedema, Atypical hemolytic uraemic syndrome, Membranoproliferative Glomerulonephritis, & Paroxysmal nocturnal hemoglobinuria) has been provided into the epidemiology (Incidence and Prevalence) section of the Complement Deficiencies and its treatment in the 8 MM countries, covering the Unit-ed States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
In terms of pharmacologic therapies, there are several drug candidates are in different Phases/ stages of development. Key assets among these are, APL-9; Apellis Pharmaceuticals, Inc., Tro-finetide; Acadia Pharmaceuticals, Inc., BIVV020; Sanofi, CAN 106; CANbridge Life Sciences Ltd., Moss-FH; Green-ovation Biotech GmbH, SLN500; Mallinckrodt plc, Zilucoplan ER; Ra Pharmaceuticals, Inc. Among these key assets, some of the assets are being designated as orphan drugs from EMA. The launch of key assets will positively impact the overall market from 2018 to 2030 in 8 MM countries. APL-9, an investigational drug, is designed to modulate the complement cascade centrally at C3 and may have the potential to treat a range of complement-mediated conditions more effectively than is possible with partial inhibitors of complement. APL-9 is a second-generation C3 modulator that leverages the same mechanism of action as Apellis’ lead compound.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,